Citi lowered the firm’s price target on BioNTech (BNTX) to $130 from $145 and keeps a Buy rating on the shares. The departures of the company’s co-founders is a surprise but the share selloff offers a good entry point, the analyst tells investors in a research note. Citi says BioNTech’s pipeline has multiple Phase 3 opportunities.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
